PMC9706046_01
eGLP-2 levels from SBS pregnant versus non-pregnant SBS
patients.. eGLP-2, endogenous glucagon-like peptide 2; SBS, short bowel syndrome.
10.1177_17562848221129787-fig1.jpg
PMC9706046_01_10.1177_17562848221129787-fig1.jpg
fig1-17562848221129787
Non-pregnant SBS patients showed lower eGLP-2 levels than the SBS pregnant patient (Figure 1). Considering that gender and anatomy type may have a strong influence in the eGLP-2 levels, we stratified patients according to gender (female or male) and the anatomy type (2 or 3); nevertheless, not differences in eGLP-2 levels between females and males, or in type 2 versus 3 anatomy group were found (Figure 1).
eGLP-2 levels paired with neonatal (cord blood) and maternal plasma samples
from the SBS pregnant patient (n = 1) and from healthy
pregnant women (without SBS, control, n = 2) at delivery
(partum) and at two points during the breastfeeding period (1 and 6 months
postpartum).. eGLP-2, endogenous glucagon-like peptide 2; SBS, short bowel syndrome.
10.1177_17562848221129787-fig2.jpg
PMC9706046_01_10.1177_17562848221129787-fig2.jpg
fig2-17562848221129787
We found that the maternal sample had higher eGLP-2 levels than neonatal sample (Figure 2), suggesting that fetal contribution to maternal eGLP2 levels would be minor. Moreover, we detected that eGLP-2 levels in samples from cord blood (neonatal) from the SBS patient were significantly inferior to those obtained from healthy pregnant women at the delivery (Figure 2). Interestingly, the pregnant SBS patient showed higher eGLP-2 levels than controls along the whole lactation period (Figure 2).